New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 31, 2013
06:09 EDTJNJ, GT, GLNCY, CTB, C, CHK, BRDCY, RDS.AOn the Fly: Periodicals Wrap-Up
WALL STREET JOURNAL: Investors in Chesapeake Energy (CHK) cheered when it announced that CEO Aubrey McClendon was leaving, but its problems won’t end there. Chesapeake cannot count on rising natural prices to help bail it out, and the company still needs to sell at least $4B in assets in 2013 to keep afloat, the Wall Street Journal reports...The yen's recent drop is giving hard-hit corporate Japan its biggest break in years, raising hopes of a long-awaited earnings recovery. Daiwa Securities estimates that profit growth at the top 200 Japanese companies will nearly double to 13% for the fiscal year through March, reversing a 16% decline in the previous year, assuming exchange rates remain roughly at current levels for two months, the Wall Street Journal reports...REUTERS: Glencore (GLNCY) is becoming a Russian oil trade leader from an outsider by mending fences in just one year with Rosneft, and is extending its grip to a sector where it played second fiddle to companies such as rival trader Vitol or Royal Dutch Shell (RDS.A), Reuters reports...Citigroup (C) is looking to pull out of consumer banking in more countries in an effort to lower costs and boost profits, sources say, Reuters reports...BLOOMBERG: Diminishing rubber supplies and record car sales are extending a five-month bull market that’s poised to raise costs for tire makers (GT, BRDCY, CTB), Bloomberg reports...Johnson & Johnson (JNJ) President Andrew Ekdahl told jurors the company recalled 93,000 all-metal hip implants because they “did not meet the clinical needs for the product” and not because they were unsafe, Bloomberg reports.
News For A;C;GT;BRDCY;CTB;JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
April 14, 2015
09:17 EDTJNJJohnson & Johnson says capital allocation strategy remains the same
The company says it continues to view dividends as its first priority in returning capital to shareholders. The company said it is still looking at portfolio for potential exits.
09:16 EDTJNJJohnson & Johnson says FY15 guidance doesn't include biosimilar compeition
Subscribe for More Information
09:16 EDTJNJJohnson & Johnson sees FY15 EPS constant currency $6.64-46.79
Sees FY15 adjusted EPS $6.04-6.19. The company had previously announced FY15 adjusted EPS $6.12-$6.27. FY15 EPS consensus $6.16
09:13 EDTJNJOn The Fly: Pre-market Movers.
UP AFTER EARNINGS: JPMorgan Chase (JPM), up 1%... Johnson & Johnson (JNJ), up marginally... Triangle Petroleum (TPLM), up 4.2%... Fastenal (FAST), up 5%. ALSO HIGHER: Brainstorm Cell Therapeutics (BCLI), up 13.5% after announcing that it will present NurOwn Phase 2a clinical data at the Academy of Neurology annual meeting... Builders FirstSource (BLDR), up 7.2% after being upgraded to Buy from Hold at Stifel... Solazyme (SZYM), up 7.5% after announcing a strategic agreement with Flotek (FTK)... Cleveland BioLabs (CBLI), up 6.8% after receiving funding recommendation from the Department of Defense... Nordic American Tanker (NAT), up 3.2% after raising quarterly dividend to 38c from 22c... Ocwen (OCN), up 3.8% after reporting preliminary fiscal 2014 results. DOWN AFTER EARNINGS: Wells Fargo (WFC), down just under 1%. ALSO LOWER: Norfolk Southern (NSC), down 5.8% after being downgraded to Hold from Buy at TD Securities... RXi Pharmaceuticals (RXII), down 14.3% after filing to sell $20M of common stock and warrants... Arrowhead Research (ARWR), down 4.5% after being downgraded to Hold from Buy at Jefferies.
08:57 EDTJNJJohnson & Johnson backs FY15 sales $75B-$76B
Including foreign exchange, sees reported sales $70B-$71B. Consensus is $71.16B. Backs FY15 net interest expense $450M-$550M. Raises FY15 net other income expense to $2B-$2.1B from $1.5B-$1.6B. Expects R&D tax credit will be renewed by Congress. Raises FY15 effective tax rate to 21%-22% from 20%-21%. If the tax credit is not approved, it will negatively impact the tax rate by 0.5%. Comments taken from Q1 earnings conference call.
07:58 EDTCCiti appoints Jamie Forese as sole president, WSJ reports
Subscribe for More Information
07:50 EDTJNJJohnson & Johnson reports Q1 Worldwide Consumer sales $3.4B
Subscribe for More Information
07:48 EDTJNJJohnson & Johnson cuts FY15 adjusted EPS to $6.04-$6.19 from $6.12-$6.27
Subscribe for More Information
07:46 EDTJNJJohnson & Johnson reports Q1 domestic sales up 5.9% to $8.69B
Subscribe for More Information
07:45 EDTJNJJohnson & Johnson reports Q1 adjusted EPS $1.56, consensus $1.54
Subscribe for More Information
April 13, 2015
17:10 EDTJNJIBM establishes a Watson Health Cloud
Subscribe for More Information
16:21 EDTJNJOn The Fly: Top stock stories for Monday
Subscribe for More Information
16:18 EDTAeBay announces executive appointments ahead of PayPal separation
Subscribe for More Information
15:38 EDTJNJNotable companies reporting before tomorrow's open
Subscribe for More Information
15:08 EDTJNJJohnson & Johnson April 100 straddle priced for 2.2% movement into Q1
14:07 EDTJNJEarnings Watch: Johnson & Johnson shares down slightly since last earnings
Subscribe for More Information
13:28 EDTJNJJohnson & Johnson April volatility elevated into Q1 and outlook
Subscribe for More Information
12:17 EDTCCiti's Bird to replace Medina-Mora, run global consumer bank, WSJ reports
Subscribe for More Information
12:05 EDTCCiti's Bird to replace Medina-Mora, run global consumer bank, Bloomberg says
Subscribe for More Information
11:12 EDTJNJJohnson & Johnson technical notes before earnings
Leading up to earnings, the shares have been trading in a narrow range largely bound by $98 at the low and $103 at the high. This trading range was preceded by a decline from the 52-week high set back in the fall of 2014. In a longer time frame, the current trading action is part of a larger potential topping process, with $95 as the midpoint. On worse than expected news, the low bound at $98 would be first important support. A breakdown below $98 would see next support at $95. A move below $95 would confirm the topping process and break the long-term uptrend. Support below $95 would be at $93.94. If results and outlook are better than expected, first resistance would be at the top of the range at $103. Next resistance would then be at $105.36. A move above that level would see $107.10, and then 52-week high and life high at $109.49 as next potential upside objectives.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use